El-Ghamrawy: Localizing the production of oncology treatments marks a qualitative leap toward achieving Egyptian pharmaceutical security.
El-Ghamrawy: Today’s achievement is the fruit of the political leadership’s support and the state’s strategy to localize the pharmaceutical industry.
El-Ghamrawy: Collaboration between state institutions and the private sector is a successful model to be followed in advancing the pharmaceutical industry.
……….
Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), participated in the press conference organized by Eva Pharma to announce the start of local production of oncology and hematology treatments at the company’s manufacturing facility in 6th of October City.
The event was attended by a number of prominent leaders and figures in the healthcare sector, including:
Prof. Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population;
Prof. Dr. Ashraf Hatem, Chairman of the Health Committee at the House of Representatives; and
Dr. Ahmed El-Sobky, Chairman of the General Authority for Healthcare.
During his speech, Dr. El-Ghamrawy stated that this project represents a major milestone in Egypt’s national pharmaceutical industry and reflects the success of the partnership between the state and the private sector in achieving self-sufficiency in high-tech biological products, ensuring the availability of safe and effective medicines of high quality for Egyptian patients.
He highlighted that the Egyptian Drug Authority has provided comprehensive technical and scientific support to Eva Pharma throughout all stages of registration, manufacturing, and evaluation, in line with the Authority’s commitment to applying the highest quality and regulatory standards. This support strengthens the EDA’s role in promoting local manufacturing initiatives and technology transfer.
The Chairman emphasized that this step aligns with the State’s vision to position Egypt as a regional hub for the manufacturing and export of biological products to neighboring countries, reaffirming the EDA’s ongoing support for all national initiatives that contribute to advancing the pharmaceutical industry and achieving sustainable health development.
The Authority has supported several ambitious initiatives to ensure the stability of pharmaceutical supplies and the transfer of advanced manufacturing technologies, leading to the localization of 208 pharmaceutical products. Moreover, the percentage of locally produced oncology medicines has increased from 47% to 64%, reflecting the tangible outcomes of the national vision to localize advanced pharmaceutical manufacturing.
For his part, Prof. Dr. Khaled Abdel Ghaffar affirmed that the State attaches great importance to localizing the pharmaceutical industry, especially in the field of biological and oncology medicines, noting that this project represents a true translation of the political leadership’s directives to achieve self-sufficiency and localize advanced technologies in Egypt.
Prof. Dr. Ashraf Hatem expressed his pride in the progress achieved by the Egyptian pharmaceutical industry, emphasizing that such milestones reflect close cooperation between the executive and legislative authorities to support this vital sector, which positively impacts the health of Egyptian citizens.
Dr. Ahmed El-Sobky stressed that today’s achievement represents another national milestone in the integrated healthcare system, pointing out that localizing the production of oncology medicines reduces the burden on patients and ensures the sustainable availability of treatment across the facilities of the General Authority for Healthcare in various governorates.